biotech · Coronary Artery Disease · Bronchopulmonary Dysplasia · ASBP
Aspire Biopharma Holdings
Aspire Biopharma Holdings clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Humacao, USA
- Founded
- 2019
- Programs
- 8
- Drugs
- 8
- Patents
- 1
Aspire Biopharma Holdings projects
8 ClinicalTrials.gov programs sponsored by Aspire Biopharma Holdings.
Aspire Biopharma Holdings has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ACT-20-MSC
Aspire Biopharma Holdings
COVID-19 Pneumonia
1 trial -
Retinol
Aspire Biopharma Holdings
Bronchopulmonary Dysplasia
1 trial -
AdreView
Aspire Biopharma Holdings
Heart Failure
1 trial -
Myocardial perfusion imaging
Aspire Biopharma Holdings
Coronary Artery Disease
1 trial -
Pulse Sequence
Aspire Biopharma Holdings
Atrial Fibrillation
1 trial -
Regadenoson
Aspire Biopharma Holdings
Coronary Artery Disease
1 trial -
Beet It Sport Shot
Aspire Biopharma Holdings
Blood Pressure
1 trial -
Nutritional Supplement
Aspire Biopharma Holdings
Healthy
1 trial
Frequently asked questions
How many clinical projects does Aspire Biopharma Holdings have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.